Thomas Gwydir - Nephros Director

NEPH Stock  USD 2.27  0.06  2.71%   

Director

Mr. Thomas Gwydir is Director of the Company since 2019.
Tenure 5 years
Address 380 Lackawanna Place, South Orange, NJ, United States, 07079
Phone201 343 5202
Webhttps://www.nephros.com
Gwydir is currently Chief Information Officer at the London Stock Exchange. Prior positions have included CIO and Chief Technology Officer at MSCI, Managing Director of Platform Services at UBS, and Vice President of Technology at Asurion. He has also held senior roles at Wells Fargo, Merrill Lynch, Dun & Bradstreet, and Magna Software. He received his B.S. in Industrial Engineering from Columbia University.

Nephros Management Efficiency

The company has return on total asset (ROA) of (0.0871) % which means that it has lost $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1827) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to -0.17. The current Return On Assets is estimated to decrease to -0.14. As of now, Nephros' Other Current Assets are increasing as compared to previous years. The Nephros' current Intangible Assets is estimated to increase to about 1.1 M, while Total Assets are projected to decrease to under 7.5 M.
The company currently holds 1.84 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Nephros has a current ratio of 5.16, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Nephros until it has trouble settling it off, either with new capital or with free cash flow. So, Nephros' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nephros sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nephros to invest in growth at high rates of return. When we think about Nephros' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Maritza MontielAptarGroup
69
Robert NelsonSharkNinja
41
Jinling ZhangViomi Technology ADR
46
De LiuViomi Technology ADR
44
Brian CarneySharkNinja
51
Alan JacksonSharkNinja
73
Giovanna MonnasAptarGroup
65
Greg ColvinSharkNinja
54
Jim McCreaSharkNinja
N/A
Jesse WuAptarGroup
62
Eugene DavisSharkNinja
62
Jesse HahnSharkNinja
N/A
Gilbert GarciaSharkNinja
53
Alain ChevassusAptarGroup
72
Joanne SmithAptarGroup
59
Andreas KramvisAptarGroup
68
Peter PfeifferAptarGroup
66
Gregory ColvinSharkNinja
57
Ralf WunderlichAptarGroup
55
Sean MaherSharkNinja
44
Weijiang WuViomi Technology ADR
40
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. Nephros (NEPH) is traded on NASDAQ Exchange in USA. It is located in 380 Lackawanna Place, South Orange, NJ, United States, 07079 and employs 31 people. Nephros is listed under Household Appliances category by Fama And French industry classification.

Management Performance

Nephros Leadership Team

Elected by the shareholders, the Nephros' board of directors comprises two types of representatives: Nephros inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nephros. The board's role is to monitor Nephros' management team and ensure that shareholders' interests are well served. Nephros' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nephros' outside directors are responsible for providing unbiased perspectives on the board's policies.
Malcom Persen, Director
Vashone Thomas, Regulatory, Quality
Thomas Gwydir, Director
Joleen Turner, VP Devel
Paul Mieyal, Director
Greg Lucas, President Systems
Robert Banks, CEO President
Alfred Vargas, Director Operations
Daron Evans, CEO and President Acting CFO, Director and Member of Audit Committee
Judy CFA, Chief Officer
Judy Mazzini, Controller
MS MBA, Inc Products
Andrew Astor, CFO, CEO
Alisa Lask, Director
Matthew Rosenberg, Director
Moshe Pinto, Director
Arthur Amron, Independent Director
Oliver Spandow, Director
Brianne McGuire, Marketing Brand

Nephros Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nephros a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Nephros offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nephros' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nephros Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nephros Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Nephros Stock analysis

When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Commodity Directory
Find actively traded commodities issued by global exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.15)
Revenue Per Share
1.371
Quarterly Revenue Growth
0.272
Return On Assets
(0.09)
Return On Equity
(0.18)
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.